Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- azathioprine
- Keftab (cephalexin)
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food interactions
cephalexin food
Applies to: Keftab (cephalexin)
ADJUST DOSING INTERVAL: Oral products containing zinc such as mineral supplements and multivitamins may interfere with the gastrointestinal absorption of cephalexin, ceftibuten or cephradine. In one pharmacokinetic study (n=12), concurrent administration of zinc sulfate (250 mg, single oral dose) and cephalexin (500 mg, single oral dose) decreased cephalexin maximum concentration (Cmax) and systemic exposure (AUC; 0-inf) by 31.05% and 27.4%, respectively. However, in the same study, when zinc sulfate was administered 3 hours after the cephalexin dose, no significant alteration in cephalexin pharmacokinetics were observed.
MANAGEMENT: Oral medications or mineral supplements that contain zinc are recommended to be administered at least 3 hours after the cephalexin, ceftibuten or cephradine dose.
References (3)
- Ding Y, Jia Y, Li F, et al. (2011) "The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin*" Br J Clin Pharmacol, 73, p. 422-7
- World Health Organization (2020) WHO Public Assessment Reports (WHOPARs) https://extranet.who.int/pqweb/medicines/prequalification-reports/whopars
- Okamura M, Terada t, KatsuraT, Saito H, Inui K (2003) "Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and beta-lactam antibiotics in human intestinal cell line Caco-2" Pharm Res, 20, p. 1389-93
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Benlysta
Benlysta infusion is used to treat active systemic lupus erythematosus (SLE) and active lupus ...
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Saphnelo
Saphnelo is used for moderate to severe SLE (lupus) for adults who are also receiving other lupus ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Tavneos
Tavneos (avacopan) is a C5a receptor antagonist used for severe active ANCA-associated vasculitis ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Kesimpta
Kesimpta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated ...
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.